期刊论文详细信息
BMC Cancer | |
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma | |
Linxiang Luo1  Cong Li2  Haifeng Yu2  Haiyan Yang2  Shuailing Peng2  Shuiyun Han2  Tao Lei2  Xi Chen2  Haiying Kong3  Xiaowu Dong4  Na Guo5  Meijuan Wu5  | |
[1] Department of Hematology, Zhejiang Quhua Hospital, Quhua, China;Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China;Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China;Department of Pharmacy, Zhejiang Medical and Health Group Hangzhou Hospital (Hangzhou Hanggang Hospital), Hangzhou, China;Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China;Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China;Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 Banshan East Road, Hangzhou, China; | |
关键词: Hodgkin lymphoma; PD-1 inhibitor; PD-L1 inhibitor; PD-L2; Molecular phenotype; Tumor microenvironment; | |
DOI : 10.1186/s12885-021-09028-4 | |
来源: Springer | |